Pathos AI raised $237 million in a Series E round led by Bristol Myers Squibb, lifting its valuation to about $3 billion. The company said it is expanding from oncology to neurological conditions with new datasets from Tempus AI and a partnership with BMS. Pathos’ stated platform, Foundry, runs thousands of AI agents that estimate clinical probability of success across assets using clinical data, genomics, specimen data, and competitive landscape inputs. Pathos plans to apply the approach first to Alzheimer’s treatments under the BMS collaboration. The financing underscores continued investor appetite for AI-driven drug discovery models, particularly those that tie agentic analytics to clinical development decision-making rather than only molecule generation. BMS’ leadership role suggests ongoing interest in leveraging machine-driven triage to improve trial selection and reduce late-stage attrition risk.